用多巴胺激动剂治疗的垂体腺瘤患者的冲动控制障碍:一个跨截面的多中心研究
Mussa H Almalki1,2, Moayad A Alsuraikh1, Eyad Almalki3
1Obesity, Endocrine, and Metabolism Center, King Fahd Medical City, Second Health Cluster, Riyadh, Saudi Arabia.
Pituitary
|February 12, 2024
概括
冲动控制障碍 (ICD) 是多巴胺激动剂 (DA) 在患有垂体腺瘤的患者中常见的副作用. 年龄较小,单身和精神疾病史增加了患上这些疾病的风险.
科学领域:
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 冲动控制障碍 (ICD) 是多巴胺激动剂 (DA) 的未被认可的副作用.
- 在内分泌条件下对DAs诱导的ICD的理解是有限的.
- 这项研究侧重于患有前性腺瘤和非功能性垂体腺瘤 (NFPA) 的患者.
研究的目的:
- 为了确定DAs诱导的ICDs的患病率在患有益生菌瘤和NFPAs的患者中.
- 确定与这些ICD相关的潜在风险因素.
- 提高内分泌学家对这种潜在副作用的认识.
主要方法:
- 横截面,多中心研究.
- 涉及200名患有前乳腺瘤和NFPAs的患者.
- 使用修改的ICD问卷进行评估.
主要成果:
- 52%的参与者报告了至少一个ICD.
- 常见的ICD包括强迫性购物 (28.5%),评价 (24.5%) 和高性欲 (24.5%).
- 年龄较小,单身和精神疾病史是ICD的重要风险因素.
结论:
- 在接受DA治疗的益生菌瘤和NFPA患者中,ICDs很常见.
- 内分泌学家必须考虑ICD作为潜在的DA副作用.
- 患有精神疾病史的患者需要特别注意.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
321
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
321
Parkinson's Disease: Overview
546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
743
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
743
Open Angle Glaucoma: Treatment
449
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
449


